Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD-iExo-001 in Atopic Dermatitis
NCT05969717Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised trial in atopic dermatitis (AD) comparing GD-iExo-001 with Placebo (2 arms). Primary endpoint: Adverse events as assessed by CTCAE at 42 days. Status: unknown.
02
Drugs
GD-iExo-001
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05969717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969717.